VEGFA and familial dilated cardiomyopathy: Compared with the DCM control group, a significant increase was observed in HGF and VEGF expression by the low-dose treatments (P < 0.05, Fig. 3a), while the high-dose treatments induced significant elevations in VEGF and IGF-1 expression (P < 0.05, Fig. 3a).